BostonGene, a leader in AI-powered drug discovery and development, announced six abstracts accepted for presentation at the 2025 ASCO Annual Meeting in Chicago (May 31 – June 3). The company will also exhibit at booth #15147.
The abstracts highlight BostonGene’s validated multimodal AI platform, which integrates deep molecular profiling, immune system characterization, and advanced analytics. These studies demonstrate how BostonGene’s technology refines patient stratification, identifies novel biomarkers, and predicts therapeutic response across various tumor types—critical advancements for oncology drug development.
Highlights of Selected Abstracts
- Molecular subtyping in sarcoma (Abstract 11536) by Nikita Kotlov explores distinct molecular patterns correlating with survival, revealing clinical insights into sarcoma biology.
- Genomic alterations in invasive lobular carcinoma (Abstract 1049), in collaboration with MD Anderson Cancer Center, identifies unique molecular features in breast cancer subtype ILC that could guide therapies.
- Gene fusion hotspots in liposarcomas (Abstract 11561) by Lev Bedniagin reveals novel RNA fusion hotspots with implications for diagnostics and therapeutics.
- Tumor microenvironment in Cancer of Unknown Primary (Abstract 4198), also with MD Anderson, associates immune response and survival, offering new perspectives on CUP.
- Tertiary lymphoid structures and immunotherapy response in NSCLC (Abstract 2634) uses AI-driven transcriptomic analysis to identify biomarkers linked to checkpoint inhibitor outcomes.
- Online-only study on prostate cancer resistance highlights the clinical use of BostonGene’s Tumor Portrait™ test in guiding treatment for castrate-resistant prostate cancer.
BostonGene’s presence at ASCO 2025 underscores the transformative impact of AI-driven precision oncology in enhancing clinical trial design and driving personalized cancer therapies.
